Gegenanzeigen · Inhixa
Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 163
HOS-137091 · Präparat HOS-097950
Enoxaparin sodium is contraindicated in patients with: • Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients listed in section 6.1; • History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies (see also section 4.4 ); • Active clinically significant bleeding and conditions with a high risk of haemorrhage, including recent haemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities; • Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for treatment in the previous 24 hours (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin (HOS-086930)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T09:35:00Z · SHA-256 bbb8302fcca3a170cc14307df6fa307c1fd979d2c3ae4a14f42ba825950d23d7 · Passage 02c7f5c127793cb47ef25c5b341b51e6536f0cc9cb7386a0baa0200dba592741 · Zeichen 0–985 im Abschnitt